| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Hyperplasia | 40 | 2016 | 523 | 3.700 |
Why?
|
| Erectile Dysfunction | 26 | 2019 | 461 | 2.100 |
Why?
|
| Prostatitis | 22 | 2011 | 102 | 1.470 |
Why?
|
| Urination Disorders | 14 | 2011 | 241 | 1.210 |
Why?
|
| Adrenergic alpha-Antagonists | 12 | 2008 | 174 | 1.120 |
Why?
|
| Pelvic Pain | 13 | 2010 | 274 | 1.010 |
Why?
|
| Urinary Retention | 5 | 2023 | 111 | 0.960 |
Why?
|
| Urology | 16 | 2020 | 399 | 0.900 |
Why?
|
| 5-alpha Reductase Inhibitors | 7 | 2016 | 107 | 0.800 |
Why?
|
| Sexual Dysfunction, Physiological | 9 | 2016 | 360 | 0.780 |
Why?
|
| Penile Erection | 6 | 2006 | 97 | 0.700 |
Why?
|
| Azasteroids | 5 | 2007 | 38 | 0.690 |
Why?
|
| Orthopoxvirus | 1 | 2018 | 11 | 0.650 |
Why?
|
| Ejaculation | 8 | 2007 | 58 | 0.640 |
Why?
|
| Finasteride | 5 | 2016 | 90 | 0.630 |
Why?
|
| Oncolytic Virotherapy | 3 | 2018 | 498 | 0.630 |
Why?
|
| Hyperthermia, Induced | 5 | 2018 | 403 | 0.600 |
Why?
|
| Phosphodiesterase Inhibitors | 7 | 2007 | 215 | 0.590 |
Why?
|
| Testicular Diseases | 2 | 2014 | 71 | 0.570 |
Why?
|
| Hospitals, Public | 1 | 2018 | 207 | 0.560 |
Why?
|
| Piperazines | 9 | 2009 | 2488 | 0.550 |
Why?
|
| Cholecystectomy | 1 | 2018 | 395 | 0.530 |
Why?
|
| Urologic Diseases | 6 | 2005 | 244 | 0.530 |
Why?
|
| Lymph Node Excision | 3 | 2018 | 1261 | 0.530 |
Why?
|
| Peritoneal Neoplasms | 5 | 2021 | 665 | 0.520 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 241 | 0.520 |
Why?
|
| Alprostadil | 3 | 2005 | 89 | 0.500 |
Why?
|
| Cystitis, Interstitial | 3 | 2008 | 61 | 0.490 |
Why?
|
| Community Health Centers | 1 | 2018 | 430 | 0.490 |
Why?
|
| Prostatism | 3 | 2008 | 14 | 0.480 |
Why?
|
| Colorectal Neoplasms | 4 | 2021 | 6773 | 0.480 |
Why?
|
| Prostatic Neoplasms | 23 | 2023 | 11124 | 0.470 |
Why?
|
| Enzyme Inhibitors | 6 | 2009 | 3798 | 0.460 |
Why?
|
| Quality of Life | 29 | 2016 | 12804 | 0.440 |
Why?
|
| Intestine, Small | 2 | 2016 | 1241 | 0.440 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 3 | 2022 | 339 | 0.440 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 1179 | 0.440 |
Why?
|
| Yohimbine | 2 | 2002 | 62 | 0.440 |
Why?
|
| Intestinal Obstruction | 1 | 2016 | 424 | 0.430 |
Why?
|
| Brachytherapy | 8 | 2014 | 1248 | 0.430 |
Why?
|
| Penile Induration | 2 | 2002 | 16 | 0.430 |
Why?
|
| Sulfones | 9 | 2009 | 437 | 0.420 |
Why?
|
| Coitus | 4 | 2006 | 133 | 0.420 |
Why?
|
| Infarction | 1 | 2013 | 244 | 0.410 |
Why?
|
| Angiomyolipoma | 1 | 2013 | 190 | 0.410 |
Why?
|
| Male | 154 | 2023 | 350118 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 3557 | 0.380 |
Why?
|
| Self Concept | 5 | 2007 | 1025 | 0.370 |
Why?
|
| Infertility, Male | 3 | 2020 | 409 | 0.360 |
Why?
|
| Hematuria | 2 | 2011 | 235 | 0.360 |
Why?
|
| Hypogonadism | 3 | 2023 | 799 | 0.360 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 1265 | 0.360 |
Why?
|
| Penile Prosthesis | 3 | 2019 | 38 | 0.360 |
Why?
|
| Neuroendocrine Tumors | 3 | 2021 | 594 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 5256 | 0.350 |
Why?
|
| Middle Aged | 109 | 2023 | 213383 | 0.340 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2022 | 980 | 0.340 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4253 | 0.330 |
Why?
|
| Phenylpropanolamine | 1 | 2008 | 15 | 0.330 |
Why?
|
| Cresols | 1 | 2008 | 28 | 0.330 |
Why?
|
| Sexual Dysfunctions, Psychological | 3 | 2016 | 187 | 0.320 |
Why?
|
| Humans | 180 | 2024 | 744343 | 0.310 |
Why?
|
| Purines | 9 | 2009 | 594 | 0.310 |
Why?
|
| Health Status Indicators | 6 | 2008 | 969 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 2728 | 0.310 |
Why?
|
| Patient Care Team | 2 | 2018 | 2531 | 0.300 |
Why?
|
| Muscarinic Antagonists | 1 | 2008 | 137 | 0.300 |
Why?
|
| Rectal Neoplasms | 1 | 2016 | 1206 | 0.300 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 2 | 2009 | 24 | 0.300 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2011 | 2245 | 0.290 |
Why?
|
| Libido | 5 | 2006 | 121 | 0.280 |
Why?
|
| Genetic Testing | 2 | 2022 | 3444 | 0.270 |
Why?
|
| Aged | 84 | 2023 | 163280 | 0.270 |
Why?
|
| SEER Program | 4 | 2021 | 1508 | 0.270 |
Why?
|
| Emergency Medical Services | 3 | 2022 | 1917 | 0.270 |
Why?
|
| Doxazosin | 4 | 2006 | 19 | 0.260 |
Why?
|
| Penile Diseases | 2 | 2020 | 46 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 11 | 2023 | 2494 | 0.260 |
Why?
|
| Insurance, Physician Services | 1 | 2004 | 24 | 0.250 |
Why?
|
| Sexuality | 3 | 2001 | 174 | 0.240 |
Why?
|
| Patient Satisfaction | 10 | 2010 | 3396 | 0.240 |
Why?
|
| Urethral Obstruction | 2 | 2003 | 56 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2018 | 20129 | 0.240 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 2400 | 0.230 |
Why?
|
| Rectum | 4 | 2014 | 904 | 0.230 |
Why?
|
| Transurethral Resection of Prostate | 4 | 2006 | 83 | 0.230 |
Why?
|
| Urinary Incontinence | 4 | 2007 | 496 | 0.230 |
Why?
|
| Laparotomy | 2 | 2016 | 473 | 0.220 |
Why?
|
| Severity of Illness Index | 12 | 2017 | 15540 | 0.220 |
Why?
|
| Liability, Legal | 1 | 2004 | 213 | 0.220 |
Why?
|
| Adult | 70 | 2021 | 214055 | 0.220 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 4262 | 0.210 |
Why?
|
| Retrospective Studies | 24 | 2022 | 77449 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.210 |
Why?
|
| Lithotripsy | 2 | 2002 | 143 | 0.210 |
Why?
|
| Benzhydryl Compounds | 1 | 2008 | 845 | 0.200 |
Why?
|
| Feasibility Studies | 5 | 2022 | 5078 | 0.200 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2021 | 234 | 0.200 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2021 | 156 | 0.190 |
Why?
|
| Andrology | 1 | 2020 | 10 | 0.190 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2017 | 85 | 0.190 |
Why?
|
| Penile Neoplasms | 1 | 2002 | 160 | 0.190 |
Why?
|
| Hepatic Artery | 1 | 2021 | 245 | 0.190 |
Why?
|
| Postoperative Complications | 8 | 2017 | 15295 | 0.180 |
Why?
|
| Ureteral Calculi | 2 | 1999 | 110 | 0.180 |
Why?
|
| Scrotum | 1 | 2020 | 115 | 0.180 |
Why?
|
| Penile Implantation | 1 | 2019 | 16 | 0.180 |
Why?
|
| Prostate | 8 | 2023 | 1774 | 0.180 |
Why?
|
| Stomach Neoplasms | 2 | 2021 | 1333 | 0.180 |
Why?
|
| Prosthesis Failure | 1 | 2005 | 1206 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2002 | 239 | 0.170 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2020 | 104 | 0.170 |
Why?
|
| Cryosurgery | 1 | 2004 | 453 | 0.170 |
Why?
|
| Sulfonamides | 3 | 2006 | 1938 | 0.170 |
Why?
|
| Enteral Nutrition | 2 | 2016 | 763 | 0.170 |
Why?
|
| Intestinal Neoplasms | 1 | 2021 | 319 | 0.170 |
Why?
|
| Female | 52 | 2022 | 380194 | 0.170 |
Why?
|
| Renal Colic | 1 | 2018 | 31 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2002 | 535 | 0.160 |
Why?
|
| Parapoxvirus | 1 | 2017 | 3 | 0.160 |
Why?
|
| Hormone Replacement Therapy | 1 | 2023 | 745 | 0.160 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 370 | 0.150 |
Why?
|
| Urologic Surgical Procedures | 1 | 2000 | 302 | 0.150 |
Why?
|
| Internship and Residency | 1 | 2018 | 5788 | 0.150 |
Why?
|
| Testosterone | 3 | 2023 | 2420 | 0.150 |
Why?
|
| Acid-Base Imbalance | 1 | 2017 | 41 | 0.150 |
Why?
|
| Aged, 80 and over | 26 | 2017 | 57776 | 0.150 |
Why?
|
| Health Priorities | 1 | 2020 | 380 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 233 | 0.150 |
Why?
|
| Health Care Surveys | 2 | 2004 | 2453 | 0.150 |
Why?
|
| Health Care Rationing | 1 | 2020 | 437 | 0.140 |
Why?
|
| Jejunostomy | 1 | 2016 | 56 | 0.140 |
Why?
|
| Hypothermia | 1 | 2018 | 189 | 0.140 |
Why?
|
| Chimera | 1 | 2018 | 485 | 0.140 |
Why?
|
| Mesentery | 1 | 2017 | 205 | 0.140 |
Why?
|
| Sexual Partners | 4 | 2007 | 730 | 0.140 |
Why?
|
| Double-Blind Method | 13 | 2021 | 12026 | 0.140 |
Why?
|
| Treatment Outcome | 21 | 2021 | 63114 | 0.140 |
Why?
|
| Sexual Behavior | 5 | 2007 | 2057 | 0.140 |
Why?
|
| Carbolines | 2 | 2010 | 265 | 0.140 |
Why?
|
| Urodynamics | 4 | 2016 | 347 | 0.140 |
Why?
|
| Axilla | 1 | 2018 | 595 | 0.140 |
Why?
|
| Luciferases | 1 | 2018 | 733 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2020 | 692 | 0.140 |
Why?
|
| Incidence | 7 | 2021 | 20947 | 0.140 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2018 | 230 | 0.140 |
Why?
|
| Medical History Taking | 4 | 2004 | 783 | 0.130 |
Why?
|
| Fecal Incontinence | 2 | 2017 | 239 | 0.130 |
Why?
|
| Methyltestosterone | 1 | 1995 | 19 | 0.130 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 146 | 0.130 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2015 | 91 | 0.130 |
Why?
|
| Quinazolines | 3 | 2008 | 1356 | 0.130 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 6364 | 0.130 |
Why?
|
| Neuroma, Acoustic | 2 | 2013 | 451 | 0.130 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2015 | 54 | 0.130 |
Why?
|
| Sigmoid Neoplasms | 1 | 2015 | 51 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 20822 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 576 | 0.130 |
Why?
|
| Temporal Bone | 2 | 2013 | 661 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 7279 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2021 | 986 | 0.120 |
Why?
|
| Managed Care Programs | 2 | 1999 | 950 | 0.120 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 454 | 0.120 |
Why?
|
| Chronic Disease | 18 | 2010 | 9146 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 1369 | 0.120 |
Why?
|
| Cardiovascular System | 1 | 2021 | 832 | 0.120 |
Why?
|
| Calculi | 1 | 2014 | 46 | 0.120 |
Why?
|
| California | 1 | 2018 | 1402 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2017 | 593 | 0.110 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 987 | 0.110 |
Why?
|
| Triage | 1 | 2020 | 976 | 0.110 |
Why?
|
| Lymphedema | 1 | 2020 | 534 | 0.110 |
Why?
|
| Laparoscopy | 2 | 2016 | 2151 | 0.110 |
Why?
|
| Urinary Tract | 1 | 1997 | 309 | 0.110 |
Why?
|
| Fibroma | 1 | 2015 | 212 | 0.110 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 1179 | 0.110 |
Why?
|
| Pelvis | 2 | 2017 | 730 | 0.110 |
Why?
|
| Alopecia | 1 | 2016 | 382 | 0.110 |
Why?
|
| Male Urogenital Diseases | 2 | 2005 | 48 | 0.110 |
Why?
|
| Platelet Transfusion | 1 | 2015 | 314 | 0.110 |
Why?
|
| Seminoma | 1 | 2013 | 137 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2013 | 247 | 0.100 |
Why?
|
| Orchiectomy | 2 | 2013 | 474 | 0.100 |
Why?
|
| Radiation Injuries | 3 | 2012 | 1180 | 0.100 |
Why?
|
| Diagnosis, Differential | 5 | 2014 | 12959 | 0.100 |
Why?
|
| Organs at Risk | 1 | 2014 | 346 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13102 | 0.100 |
Why?
|
| Cohort Studies | 11 | 2021 | 40561 | 0.100 |
Why?
|
| Prostatectomy | 5 | 2005 | 1890 | 0.100 |
Why?
|
| Nocturia | 1 | 2011 | 19 | 0.100 |
Why?
|
| Catheters, Indwelling | 1 | 2014 | 426 | 0.100 |
Why?
|
| Program Development | 1 | 2018 | 1316 | 0.100 |
Why?
|
| Societies, Medical | 10 | 2016 | 3743 | 0.100 |
Why?
|
| Renal Artery | 1 | 2013 | 398 | 0.100 |
Why?
|
| Trauma Centers | 1 | 2016 | 890 | 0.100 |
Why?
|
| United States | 24 | 2020 | 69872 | 0.100 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 15165 | 0.100 |
Why?
|
| Necrosis | 2 | 2013 | 1643 | 0.090 |
Why?
|
| Autoantibodies | 2 | 2011 | 2035 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 950 | 0.090 |
Why?
|
| Microspheres | 1 | 2013 | 777 | 0.090 |
Why?
|
| Melanoma | 2 | 2020 | 5510 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 7913 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 1058 | 0.090 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 537 | 0.090 |
Why?
|
| Malnutrition | 1 | 2016 | 625 | 0.090 |
Why?
|
| Urography | 3 | 2008 | 313 | 0.090 |
Why?
|
| Virus Replication | 1 | 2018 | 2534 | 0.090 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2010 | 101 | 0.090 |
Why?
|
| Disinfectants | 1 | 2011 | 116 | 0.090 |
Why?
|
| Logistic Models | 6 | 2016 | 13408 | 0.090 |
Why?
|
| Radiosurgery | 2 | 2013 | 1329 | 0.090 |
Why?
|
| Lymph Nodes | 2 | 2020 | 3474 | 0.090 |
Why?
|
| Cystoscopy | 4 | 2008 | 134 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 302 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2018 | 1181 | 0.090 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 1164 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2021 | 3461 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2013 | 924 | 0.080 |
Why?
|
| Adaptation, Psychological | 4 | 2007 | 2576 | 0.080 |
Why?
|
| Disinfection | 1 | 2011 | 191 | 0.080 |
Why?
|
| Androgens | 1 | 2016 | 1281 | 0.080 |
Why?
|
| Patient Selection | 2 | 2020 | 4215 | 0.080 |
Why?
|
| Ireland | 3 | 2022 | 161 | 0.080 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 1540 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 1671 | 0.080 |
Why?
|
| Epidemiologic Methods | 3 | 2009 | 1364 | 0.080 |
Why?
|
| Parenteral Nutrition | 1 | 2013 | 650 | 0.080 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2416 | 0.080 |
Why?
|
| Radiation Protection | 1 | 2012 | 419 | 0.080 |
Why?
|
| Cochlear Implants | 1 | 1993 | 339 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 3616 | 0.080 |
Why?
|
| American Heart Association | 2 | 2024 | 1056 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 14722 | 0.080 |
Why?
|
| Respiration, Artificial | 2 | 2016 | 2569 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2007 | 9959 | 0.080 |
Why?
|
| Brain Stem | 1 | 1993 | 846 | 0.080 |
Why?
|
| Personal Satisfaction | 4 | 2007 | 643 | 0.080 |
Why?
|
| Angiography | 1 | 2013 | 1639 | 0.080 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2007 | 62 | 0.080 |
Why?
|
| Vision Screening | 1 | 2008 | 66 | 0.080 |
Why?
|
| Ischemia | 1 | 2016 | 1907 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2014 | 804 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2014 | 1275 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 4851 | 0.070 |
Why?
|
| Aging | 3 | 2003 | 8664 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2016 | 2250 | 0.070 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 731 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2009 | 977 | 0.070 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 598 | 0.070 |
Why?
|
| Triazines | 1 | 2009 | 315 | 0.070 |
Why?
|
| Ciprofloxacin | 2 | 2004 | 315 | 0.070 |
Why?
|
| Follow-Up Studies | 9 | 2017 | 39050 | 0.070 |
Why?
|
| Radiation Dosage | 2 | 2013 | 1928 | 0.070 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 190 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 1583 | 0.070 |
Why?
|
| Age Factors | 5 | 2018 | 18370 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 1182 | 0.070 |
Why?
|
| Prazosin | 1 | 2006 | 96 | 0.070 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2007 | 238 | 0.070 |
Why?
|
| Decision Making | 1 | 2020 | 3887 | 0.070 |
Why?
|
| Massage | 1 | 2006 | 85 | 0.070 |
Why?
|
| Ultrasonography | 3 | 2014 | 5985 | 0.070 |
Why?
|
| Multivariate Analysis | 8 | 2021 | 12245 | 0.070 |
Why?
|
| Length of Stay | 3 | 2017 | 6309 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2006 | 6489 | 0.070 |
Why?
|
| Time Factors | 8 | 2016 | 40075 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2015 | 2240 | 0.070 |
Why?
|
| Isoelectric Focusing | 1 | 2005 | 181 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4838 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 1677 | 0.070 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 279 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2013 | 1590 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1363 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 11524 | 0.060 |
Why?
|
| Health Surveys | 7 | 2011 | 4037 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1624 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2003 | 1130 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1792 | 0.060 |
Why?
|
| Prevalence | 9 | 2014 | 15226 | 0.060 |
Why?
|
| Urination | 2 | 2016 | 204 | 0.060 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2015 | 369 | 0.060 |
Why?
|
| Risk Factors | 10 | 2017 | 72290 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 16689 | 0.060 |
Why?
|
| Cross Infection | 2 | 2011 | 1416 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2007 | 548 | 0.060 |
Why?
|
| Community Health Nursing | 1 | 2004 | 24 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 1121 | 0.060 |
Why?
|
| Urethra | 2 | 2003 | 408 | 0.060 |
Why?
|
| Data Collection | 4 | 2002 | 3341 | 0.060 |
Why?
|
| Clostridium Infections | 1 | 2011 | 548 | 0.060 |
Why?
|
| Nurse Clinicians | 1 | 2004 | 31 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2016 | 15076 | 0.060 |
Why?
|
| Syndrome | 4 | 2006 | 3251 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 8388 | 0.060 |
Why?
|
| Psychological Tests | 1 | 2006 | 651 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 1990 | 788 | 0.060 |
Why?
|
| Infection Control | 1 | 2011 | 966 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2016 | 11031 | 0.060 |
Why?
|
| Analgesics | 1 | 2010 | 1040 | 0.060 |
Why?
|
| Nephrectomy | 2 | 2000 | 1050 | 0.060 |
Why?
|
| Young Adult | 11 | 2021 | 56430 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 841 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2008 | 3923 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 2872 | 0.060 |
Why?
|
| Imidazoles | 1 | 2009 | 1206 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1839 | 0.050 |
Why?
|
| Eye Diseases | 1 | 2008 | 669 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5317 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2006 | 1588 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 780 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2002 | 153 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2002 | 331 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2002 | 322 | 0.050 |
Why?
|
| Plasmodium falciparum | 1 | 2011 | 1732 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2015 | 3110 | 0.050 |
Why?
|
| Rest | 1 | 2006 | 901 | 0.050 |
Why?
|
| Protein Array Analysis | 3 | 2011 | 411 | 0.050 |
Why?
|
| Scotland | 1 | 2021 | 155 | 0.050 |
Why?
|
| Proteomics | 2 | 2005 | 3638 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2002 | 462 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2006 | 1988 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2008 | 1359 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 5686 | 0.050 |
Why?
|
| Hospitalization | 2 | 2019 | 10262 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 1641 | 0.050 |
Why?
|
| Comorbidity | 5 | 2006 | 10388 | 0.050 |
Why?
|
| Methods | 1 | 2001 | 1129 | 0.050 |
Why?
|
| Age Distribution | 2 | 2003 | 2902 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 17446 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2003 | 1172 | 0.050 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 103 | 0.050 |
Why?
|
| Critical Illness | 1 | 2013 | 2670 | 0.050 |
Why?
|
| Police | 1 | 2022 | 149 | 0.050 |
Why?
|
| Pacemaker, Artificial | 1 | 2006 | 816 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 350 | 0.040 |
Why?
|
| Risk Assessment | 4 | 2016 | 23338 | 0.040 |
Why?
|
| Gastric Bypass | 1 | 2008 | 812 | 0.040 |
Why?
|
| Private Practice | 1 | 2000 | 154 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 3610 | 0.040 |
Why?
|
| Estradiol | 1 | 2007 | 2020 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2007 | 3420 | 0.040 |
Why?
|
| Pressure | 1 | 2003 | 1203 | 0.040 |
Why?
|
| Cost of Illness | 2 | 2011 | 1859 | 0.040 |
Why?
|
| Prospective Studies | 10 | 2021 | 53288 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 7659 | 0.040 |
Why?
|
| Life Style | 2 | 2009 | 3835 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2002 | 733 | 0.040 |
Why?
|
| Qualitative Research | 2 | 2007 | 2682 | 0.040 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 1999 | 75 | 0.040 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 4644 | 0.040 |
Why?
|
| Canada | 3 | 2010 | 2065 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2001 | 651 | 0.040 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 19905 | 0.040 |
Why?
|
| Baltimore | 2 | 2008 | 231 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 1213 | 0.040 |
Why?
|
| Europe | 2 | 2020 | 3339 | 0.040 |
Why?
|
| Disease Progression | 4 | 2015 | 13284 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2016 | 35421 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2008 | 3022 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 794 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 2879 | 0.040 |
Why?
|
| Ileus | 1 | 2017 | 58 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2004 | 2539 | 0.040 |
Why?
|
| Utilization Review | 1 | 2018 | 392 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 972 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 1420 | 0.040 |
Why?
|
| Mutation | 2 | 2020 | 29786 | 0.040 |
Why?
|
| Rabbits | 1 | 2003 | 4894 | 0.040 |
Why?
|
| Mitomycin | 1 | 2017 | 259 | 0.040 |
Why?
|
| Ileostomy | 1 | 2017 | 119 | 0.040 |
Why?
|
| Potassium, Dietary | 1 | 1996 | 96 | 0.030 |
Why?
|
| ROC Curve | 3 | 2016 | 3527 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 99 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 86 | 0.030 |
Why?
|
| Morbidity | 2 | 2017 | 1769 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 9239 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2016 | 152 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 1149 | 0.030 |
Why?
|
| Drug Therapy | 1 | 1999 | 497 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 408 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2004 | 941 | 0.030 |
Why?
|
| Anastomotic Leak | 1 | 2017 | 162 | 0.030 |
Why?
|
| Mucin-4 | 1 | 2015 | 37 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2001 | 868 | 0.030 |
Why?
|
| Prognosis | 6 | 2017 | 29063 | 0.030 |
Why?
|
| Vietnam | 1 | 2015 | 408 | 0.030 |
Why?
|
| Prostatic Diseases | 1 | 1995 | 56 | 0.030 |
Why?
|
| Health Status Disparities | 2 | 2022 | 1797 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1996 | 287 | 0.030 |
Why?
|
| Colon, Sigmoid | 1 | 2015 | 120 | 0.030 |
Why?
|
| Serum | 2 | 2006 | 214 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1788 | 0.030 |
Why?
|
| Health Status | 2 | 2007 | 4034 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2004 | 1439 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 767 | 0.030 |
Why?
|
| Health Services Accessibility | 2 | 2008 | 5137 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2004 | 11725 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 327 | 0.030 |
Why?
|
| Depressive Disorder | 1 | 2006 | 3748 | 0.030 |
Why?
|
| Psychometrics | 4 | 2007 | 3002 | 0.030 |
Why?
|
| Hearing Loss, Bilateral | 1 | 1993 | 54 | 0.030 |
Why?
|
| Ear | 1 | 2013 | 173 | 0.030 |
Why?
|
| Magnesium | 1 | 1996 | 813 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2022 | 8324 | 0.030 |
Why?
|
| Urine | 2 | 2006 | 370 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2016 | 447 | 0.030 |
Why?
|
| Hospitals | 2 | 2020 | 3952 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 1996 | 418 | 0.030 |
Why?
|
| Leadership | 1 | 2022 | 1357 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1993 | 1681 | 0.030 |
Why?
|
| Lymphatic System | 1 | 2013 | 253 | 0.030 |
Why?
|
| Boston | 3 | 2011 | 9313 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2016 | 663 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2015 | 10252 | 0.030 |
Why?
|
| Hypertension | 2 | 2006 | 8480 | 0.030 |
Why?
|
| Depression | 1 | 2011 | 7766 | 0.030 |
Why?
|
| Delayed-Action Preparations | 2 | 2006 | 968 | 0.030 |
Why?
|
| Carcinoma | 1 | 2003 | 2375 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 1360 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2017 | 1915 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 21746 | 0.020 |
Why?
|
| Health Education | 2 | 2008 | 1056 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 3703 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 3689 | 0.020 |
Why?
|
| Focus Groups | 2 | 2007 | 1321 | 0.020 |
Why?
|
| Cisplatin | 1 | 2017 | 1662 | 0.020 |
Why?
|
| Endemic Diseases | 1 | 2011 | 182 | 0.020 |
Why?
|
| Decontamination | 1 | 2011 | 69 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2008 | 2618 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2015 | 1100 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2018 | 1041 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2011 | 253 | 0.020 |
Why?
|
| Malaria Vaccines | 1 | 2011 | 158 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 2043 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 990 | 0.020 |
Why?
|
| Cross-Sectional Studies | 4 | 2020 | 25043 | 0.020 |
Why?
|
| Physical Examination | 2 | 2008 | 1237 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2014 | 492 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2007 | 2971 | 0.020 |
Why?
|
| Internet | 1 | 2002 | 3064 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 8642 | 0.020 |
Why?
|
| China | 1 | 2015 | 2248 | 0.020 |
Why?
|
| Interferon-beta | 1 | 1991 | 323 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2004 | 4558 | 0.020 |
Why?
|
| Neurofibromatosis 2 | 1 | 1993 | 380 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2011 | 322 | 0.020 |
Why?
|
| Kenya | 1 | 2011 | 685 | 0.020 |
Why?
|
| Survival Rate | 2 | 2021 | 12788 | 0.020 |
Why?
|
| Agranulocytosis | 1 | 1988 | 101 | 0.020 |
Why?
|
| Adolescent | 9 | 2021 | 85781 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 2133 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1602 | 0.020 |
Why?
|
| Propensity Score | 1 | 2015 | 1781 | 0.020 |
Why?
|
| Radiometry | 1 | 2014 | 800 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 571 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 1996 | 1226 | 0.020 |
Why?
|
| Speech Perception | 1 | 1993 | 489 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 4042 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1996 | 2765 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2016 | 1609 | 0.020 |
Why?
|
| Registries | 1 | 2024 | 8089 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1993 | 1842 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2015 | 1434 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1991 | 542 | 0.020 |
Why?
|
| Animals | 3 | 2017 | 168757 | 0.020 |
Why?
|
| Office Visits | 2 | 2004 | 598 | 0.020 |
Why?
|
| International Cooperation | 2 | 2004 | 1420 | 0.020 |
Why?
|
| Administration, Oral | 1 | 1995 | 3913 | 0.020 |
Why?
|
| Species Specificity | 1 | 2011 | 2478 | 0.020 |
Why?
|
| Social Support | 2 | 2007 | 2118 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 896 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2011 | 9849 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2002 | 3523 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2011 | 6314 | 0.020 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2006 | 28 | 0.020 |
Why?
|
| Hydrogels | 1 | 2012 | 724 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 7785 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1997 | 2948 | 0.020 |
Why?
|
| Ureteral Diseases | 1 | 1986 | 61 | 0.020 |
Why?
|
| Medicare | 1 | 2004 | 6566 | 0.020 |
Why?
|
| Urethritis | 1 | 2005 | 23 | 0.020 |
Why?
|
| Carbocyanines | 1 | 2006 | 174 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2019 | 3209 | 0.020 |
Why?
|
| Radiography | 2 | 2015 | 7023 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 1486 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2005 | 65 | 0.020 |
Why?
|
| Consumer Health Information | 1 | 2008 | 211 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 1380 | 0.020 |
Why?
|
| Anions | 1 | 2005 | 133 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2011 | 2559 | 0.020 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2005 | 76 | 0.020 |
Why?
|
| HIV Infections | 1 | 2011 | 16718 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2015 | 1470 | 0.020 |
Why?
|
| Calgranulin B | 1 | 2005 | 84 | 0.020 |
Why?
|
| Risk | 2 | 2009 | 9687 | 0.020 |
Why?
|
| Patient Care Planning | 2 | 2004 | 921 | 0.020 |
Why?
|
| Norway | 1 | 2006 | 448 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 2886 | 0.020 |
Why?
|
| Body Fluids | 1 | 2006 | 319 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2007 | 940 | 0.020 |
Why?
|
| Direct Service Costs | 1 | 2004 | 62 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2004 | 235 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 977 | 0.020 |
Why?
|
| Haptoglobins | 1 | 2005 | 165 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2015 | 4026 | 0.020 |
Why?
|
| Anger | 1 | 2006 | 402 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1996 | 3188 | 0.010 |
Why?
|
| Serpins | 1 | 2005 | 247 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1991 | 2007 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 905 | 0.010 |
Why?
|
| Gene Expression | 1 | 2016 | 7799 | 0.010 |
Why?
|
| Neutropenia | 1 | 1988 | 895 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1998 | 3143 | 0.010 |
Why?
|
| Prejudice | 1 | 2007 | 570 | 0.010 |
Why?
|
| Malaria, Falciparum | 1 | 2011 | 1077 | 0.010 |
Why?
|
| Hematoma | 1 | 2008 | 758 | 0.010 |
Why?
|
| Professional Practice | 2 | 1995 | 326 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1986 | 1032 | 0.010 |
Why?
|
| Absenteeism | 1 | 2004 | 250 | 0.010 |
Why?
|
| Algorithms | 2 | 2018 | 13881 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2002 | 173 | 0.010 |
Why?
|
| Research Design | 1 | 1998 | 5987 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2017 | 4445 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2002 | 295 | 0.010 |
Why?
|
| Translations | 1 | 2001 | 64 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2003 | 503 | 0.010 |
Why?
|
| Vasodilation | 1 | 2006 | 944 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 6622 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 318 | 0.010 |
Why?
|
| Nurse's Role | 1 | 2003 | 209 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 1405 | 0.010 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 976 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1993 | 1876 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5952 | 0.010 |
Why?
|
| Fever | 1 | 1988 | 1616 | 0.010 |
Why?
|
| Family Practice | 1 | 2004 | 516 | 0.010 |
Why?
|
| Otitis Media | 1 | 2003 | 277 | 0.010 |
Why?
|
| Facial Nerve | 1 | 2003 | 271 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2006 | 2029 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 2557 | 0.010 |
Why?
|
| Health Services Research | 1 | 2008 | 1836 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2005 | 1124 | 0.010 |
Why?
|
| Educational Status | 1 | 2008 | 2540 | 0.010 |
Why?
|
| Semen | 1 | 2002 | 316 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 634 | 0.010 |
Why?
|
| Placebos | 1 | 2004 | 1676 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 2003 | 2708 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2013 | 3679 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2011 | 4560 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2001 | 298 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2006 | 2715 | 0.010 |
Why?
|
| Urban Population | 1 | 2007 | 2021 | 0.010 |
Why?
|
| Lasers | 1 | 2003 | 952 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2505 | 0.010 |
Why?
|
| Abscess | 1 | 1983 | 607 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2006 | 1827 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 3870 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2008 | 12720 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 1425 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 4982 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1988 | 1886 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 5179 | 0.010 |
Why?
|
| Epinephrine | 1 | 2001 | 792 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2006 | 1917 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2001 | 642 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 2203 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4933 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2006 | 1401 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2008 | 2266 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2008 | 2684 | 0.010 |
Why?
|
| Microsurgery | 1 | 2003 | 796 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2002 | 1179 | 0.010 |
Why?
|
| Mental Health | 1 | 2011 | 3019 | 0.010 |
Why?
|
| Weight Loss | 1 | 2008 | 2622 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1990 | 5391 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 1996 | 109 | 0.010 |
Why?
|
| Abdomen | 1 | 1983 | 1118 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2005 | 8949 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2003 | 1533 | 0.010 |
Why?
|
| Retirement | 1 | 1998 | 215 | 0.010 |
Why?
|
| Bone Marrow Neoplasms | 1 | 1997 | 104 | 0.010 |
Why?
|
| Cell Line | 2 | 2006 | 15997 | 0.010 |
Why?
|
| Endoscopy | 1 | 1986 | 1785 | 0.010 |
Why?
|
| Personnel Selection | 1 | 1998 | 189 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2001 | 1240 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1996 | 6459 | 0.010 |
Why?
|
| Health Behavior | 1 | 2007 | 2636 | 0.010 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 1995 | 92 | 0.010 |
Why?
|
| Bacteria | 1 | 2006 | 2114 | 0.010 |
Why?
|
| Flutamide | 1 | 1995 | 96 | 0.010 |
Why?
|
| Consensus | 1 | 2004 | 2959 | 0.010 |
Why?
|
| Sex Factors | 1 | 2009 | 10397 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 1622 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 13695 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7149 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1998 | 662 | 0.010 |
Why?
|
| HIV-1 | 1 | 2011 | 6939 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 10943 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 2278 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 3229 | 0.010 |
Why?
|
| Individuality | 1 | 1995 | 307 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 5102 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2004 | 2071 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2002 | 3023 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 2124 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4245 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12797 | 0.010 |
Why?
|
| Infant | 3 | 2002 | 35136 | 0.010 |
Why?
|
| Massachusetts | 1 | 2003 | 8663 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2000 | 1643 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 18111 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1997 | 2513 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2003 | 6256 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 9274 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1995 | 1205 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1991 | 708 | 0.010 |
Why?
|
| Proteins | 1 | 2003 | 6103 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 10638 | 0.000 |
Why?
|
| Cell Count | 1 | 1991 | 1856 | 0.000 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 6895 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9648 | 0.000 |
Why?
|
| Endoscopes | 1 | 1986 | 175 | 0.000 |
Why?
|
| Ureteral Neoplasms | 1 | 1986 | 111 | 0.000 |
Why?
|
| Dilatation | 1 | 1986 | 291 | 0.000 |
Why?
|
| Ureteral Obstruction | 1 | 1986 | 296 | 0.000 |
Why?
|
| Attitude of Health Personnel | 1 | 1995 | 3843 | 0.000 |
Why?
|
| Child, Preschool | 2 | 1996 | 41006 | 0.000 |
Why?
|
| Neoplasms | 1 | 1988 | 21683 | 0.000 |
Why?
|
| Child | 3 | 1996 | 77709 | 0.000 |
Why?
|
| Drainage | 1 | 1983 | 1142 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1991 | 19229 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1988 | 25625 | 0.000 |
Why?
|